Atacicept cut kidney-disease progression in IgA nephropathy, final trial shows

Atacicept, an antibody-like drug that mops up two immune-signalling proteins driving IgA nephropathy, slowed the loss of kidney function and sharply reduced the share of patients whose disease progressed in the final analysis of the phase 3 ORIGIN 3 trial [s1]. The result moves the drug past the surrogate measures that have defined this field's recent approvals and toward the outcome patients actually care about: keeping their kidneys working [s1].

IgA nephropathy is an autoimmune kidney disease in which the body makes a faulty, sugar-stripped form of the antibody immunoglobulin A, called galactose-deficient IgA1. Immune complexes built around that antibody lodge in the kidney's filtering units and inflame them, leaking protein into the urine and, over years, eroding the estimated glomerular filtration rate (eGFR) that gauges how well the kidneys clear waste. It is a leading cause of kidney failure in young adults. Atacicept works upstream of the damage, blocking two signals — APRIL and BAFF — that B cells need to produce the culprit antibody [s1].

What the trial did

ORIGIN 3 was a randomised, double-blind, placebo-controlled phase 3 trial funded by Vera Therapeutics, which is developing atacicept [s1][s2]. It enrolled adults with biopsy-confirmed IgA nephropathy who remained at risk of progression despite standard background therapy, and assigned them to weekly subcutaneous atacicept 150 mg or matching placebo [s1]. Of 431 patients randomised, 428 received at least one dose, split evenly at 214 per group [s1]. The trial was designed to read out first on proteinuria — the protein-leakage signal that has supported accelerated approvals across this drug class — and then, in this final analysis, on the harder measures of preserved kidney function and clinical progression [s1].

What it found

Kidney function held steady on the drug and declined on placebo. Over the first year of treatment the mean change in eGFR was close to flat with atacicept but fell with placebo, a difference that was highly statistically significant (P<0.001), and the gap in the rate of eGFR decline widened through two years of follow-up on the same side (P<0.001) [s1]. A stable eGFR in a disease defined by its slow downhill slope is the signal nephrologists have been waiting for from this class [s1].

The clearest number is the composite of disease progression — a confirmed sustained drop in eGFR, kidney failure, or death from kidney or cardiovascular causes. That endpoint occurred in 5.1% of the atacicept group versus 17.8% of the placebo group, a hazard ratio of 0.24 (P<0.001), meaning the drug cut the rate of progression by roughly three-quarters [s1]. No patient taking atacicept progressed to dialysis, a kidney transplant, or death, a notable observation even acknowledging the short follow-up for events that usually take many more years to accrue [s1].

Safety looked clean for a drug that suppresses antibody production. Adverse events occurred in 74.8% of the atacicept group and 78.0% of the placebo group, and serious adverse events were actually less common on the drug — 7.0% versus 15.4% — a pattern consistent with fewer disease-driven complications [s1]. One death occurred, in the placebo group [s1].

How to read it

This is a stronger result than the one that defined the class's last big read-out. An earlier endothelin-blocking drug, atrasentan, slowed kidney decline in its own phase 3 trial but narrowly missed statistical significance on its primary eGFR comparison. Atacicept clears that bar with room to spare: the eGFR comparisons were highly significant and the progression composite showed a large, consistent effect [s1]. The lower rate of serious adverse events on an immunosuppressant is reassuring, though the follow-up is still measured in a few years, not the decades over which IgA nephropathy destroys kidneys.

The caveat is the one that applies to every drug in this fast-moving field: ORIGIN 3 tested atacicept against placebo on top of standard care, not head-to-head against the other new agents — SGLT2 inhibitors, endothelin blockers, and the APRIL-targeting antibody sibeprenlimab, which the FDA cleared on proteinuria alone. Which of these to use, in what order, and in what combination is a question none of the individual trials answers [s1].

What to watch

The practical questions now are regulatory and comparative. A progression benefit of this size, backed by significant eGFR data rather than proteinuria alone, is the kind of evidence that supports a full approval rather than an accelerated one [s1]. Longer follow-up will show whether the complete absence of dialysis, transplant, and death on the drug holds as the cohort ages, and whether atacicept's B-cell suppression carries any delayed infection risk the trial period was too short to reveal [s1].

This article describes research and regulatory context and is not medical advice. Treatment of IgA nephropathy is a decision for treating clinicians.